INTS
NASDAQ · Biotechnology
Intensity Therapeutics Inc
$3.96
-0.04 (-1.00%)
Open$4.01
Previous Close$4.00
Day High$4.19
Day Low$3.90
52W High$43.50
52W Low$3.51
Volume—
Avg Volume31.1K
Market Cap11.49M
P/E Ratio—
EPS$-7.18
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+834.3% upside
Current
$3.96
$3.96
Target
$37.00
$37.00
$31.85
$37.00 avg
$43.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.04M | 2.78M | 2.85M |
| Net Income | -338,512 | -296,423 | -392,127 |
| Profit Margin | -11.1% | -10.7% | -13.8% |
| EBITDA | -526,054 | -452,617 | -411,641 |
| Free Cash Flow | -211,518 | -295,521 | -239,156 |
| Rev Growth | +8.4% | -9.6% | +19.4% |
| Debt/Equity | 0.32 | 0.33 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |